An open label phase I clinical intervention, dose-escalation study assessing the feasibility of assessing the local distribution of fluorescently labelled vedolizumab after intravenous administration in gut tissue in patients with Inflammatory-bowel-disease
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacodynamics; Pharmacokinetics
- 09 Dec 2021 New trial record